ROSE PHARMA A/S: Financial statements 2012
CVR: 27174965
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
ROSE PHARMA A/S (CVR 27174965) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK -335,391 and a net result of DKK -335,146. Equity in the 2012 report amounted to DKK 1,101,940. The solvency ratio was 70.8%.
- Gross Profit
- DKK -335,391
- Profit/Loss
- DKK -335,146
- Equity
- DKK 1,101,940
- Total Assets
- DKK 1,556,382
Official annual report
Keep an eye on ROSE PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of June 19, 2012, Florian Schønharting has joined the board of directors of ROSE PHARMA A/S.
As of June 19, 2012, Enda Kenny has left the board of directors of ROSE PHARMA A/S.
As of June 7, 2012, Pryds Statsautoriseret Revisionsfirma has been appointed auditor of ROSE PHARMA A/S.
As of June 7, 2012, Florian Schønharting has left the board of directors of ROSE PHARMA A/S.
As of January 26, 2012, Enda Kenny has joined the board of directors of ROSE PHARMA A/S.
As of January 26, 2012, Christian Karsten Hansen has left the board of directors of ROSE PHARMA A/S.
As of January 26, 2012, Olof Gustav Paulus Isaksson has left the board of directors of ROSE PHARMA A/S.
As of January 26, 2012, Charles Woler has left the board of directors of ROSE PHARMA A/S.
As of January 26, 2012, Leif Helth Jensen is registered as adm. dir of ROSE PHARMA A/S.
As of January 26, 2012, Michael Forer is registered as chairman of ROSE PHARMA A/S.
About ROSE PHARMA A/S
ROSE PHARMA A/S was a Danish company of the type Aktieselskab based in Roskilde, founded in 2003. The company has been dissolved on 23 April 2020. The company was registered under the industry Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company has 1 employee (2007). In 2016, the company reported a gross profit of DKK -35,218 and a net result of DKK -51,821 compared with DKK -186,905 the year before. Equity in the 2016 report amounted to DKK 979,327.